Karmed Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 27-10-2024
- Paid Up Capital ₹ 0.10 M
as on 27-10-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 8220.79%
(FY 2023)
- Profit 560.38%
(FY 2023)
- Ebitda 2243.40%
(FY 2023)
- Net Worth 3.49%
(FY 2023)
- Total Assets 90.69%
(FY 2023)
About Karmed Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Kumra, Monika Kumra, and Arjun Kumra serve as directors at the Company.
- CIN/LLPIN
U24100DL2021PTC383831
- Company No.
383831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Karmed Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Kumra  | Director | 17-Jul-2021 | Current |
| Monika Kumra | Director | 17-Jul-2021 | Current |
| Arjun Kumra | Director | 17-Jul-2021 | Current |
Financial Performance of Karmed Lifesciences.
Karmed Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 8220.79% increase. The company also saw a substantial improvement in profitability, with a 560.38% increase in profit. The company's net worth moved up by a moderate rise of 3.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Karmed Lifesciences?
Unlock access to Karmed Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kumra Pharma Private LimitedActive 29 years 25 daysAtul Kumra, Monika Kumra and 1 more are mutual person
Medicine House Worldwide Pharmaceuticals Private LimitedActive 9 years 2 monthsAtul Kumra and Arjun Kumra are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Karmed Lifesciences?
Karmed Lifesciences has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Karmed Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Karmed Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
